Health & Biotech
ASX Health Stocks: Neurotech says its cannabis strain works well when combined with Diclofenac
Health & Biotech
Check Up: Biotechs are getting crushed, but expert says we shouldn’t dismiss them
Health & Biotech
Prescient unveils its latest powerful platform to advance personalised targeted cancer treatments
Health & Biotech
ASX Health Stocks: Race Oncology is set to expand its clinical trial to Spain and Italy
Health & Biotech
Dimerix enters deal to advance trial into treatment for diabetic kidney disease
Health & Biotech
ASX Health Stocks: Orthocell reports positive results from nerves reconstruction trial
Health & Biotech
Nanollose to launch Lee Mathews designed garment at Copenhagen global fashion summit
Health & Biotech
Could Aussie cannabinoid companies help solve a global opioid crisis?
Health & Biotech
MGC Pharma results provides real hope for Alzheimer’s sufferers
Health & Biotech
ASX Health Stocks: Clarity Pharma gets the go-ahead from US FDA
Health & Biotech
Dr Boreham’s Crucible: Will AstraZeneca cash put Starpharma on a rocket back to all-time highs?
Health & Biotech
Weed Week: Sydney Uni says it’s okay to CBD ‘n drive, and cannabis-infused drinks on the rise
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.